<PRE>                                                                                                                             
03 SEP 2010 05:51                     LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES                                      
                                                                                                                                  
                                                                                       REGS. REGS. REGS. REGS. REGS.              
                                       R                                                LAST  LAST  LAST  LAST  LAST  # of  # of  
                                       E                                   ACCR. TOTAL    12     6     3    30     7  ACT.  CURR  
STUDY                                  G ARM                                GOAL REGS. Month Month Month  DAYS  DAYS INSTs  IRBs  
-------------------------------------- - --------------------------------- ----- ----- ----- ----- ----- ----- ----- ----- -----  
S9007-Cytogen. Studies in Leuk. Pts.   1 1  cytogenetics sample                   3314    71    17     2     1     0   338   115  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                  3314    71    17     2     1     0              
                                                                                                                                  
                                                                                                                                  
S9910-Leuk Central Lab/Tissue Repos    1 1  Specimen submission                   1265    72    16     2     1     0   294   108  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                  1265    72    16     2     1     0              
                                                                                                                                  
                                                                                                                                  
S0106-AML, Mylotarg/Ara-C/Daunomycin   1 1  ARA-C + Daunomycin + Mylotarg    684   317     0     0     0     0     0           1  
                                         2  ARA-C + Daunomycin                     320     0     0     0     0     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                   637     0     0     0     0     0              
                                                                                                                                  
                                       2 3  ARA-C Consolidation                    403     5     0     0     0     0           1  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                   403     5     0     0     0     0              
                                                                                                                                  
                                       3 4  Mylotarg                         342    91     0     0     0     0     0           1  
                                         5  Observation                             91     0     0     0     0     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                   182     0     0     0     0     0              
                                                                                                                                  
                                                                                                                                  
S0333-Non-L3 ALL, Double Induction     1 1  DNR + VCR + Pred + PEG-L-Asp      78    79     2     0     0     0     0    27     4  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    79     2     0     0     0     0              
                                                                                                                                  
                                       2 2  HD ARA-C + Mitoxantrone + GCSF          57     1     0     0     0     0    27     4  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    57     1     0     0     0     0              
                                                                                                                                  
                                       3 3  CTX + ARA-C + 6-MP + MTX +GCSF          40     2     0     0     0     0    27     4  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    40     2     0     0     0     0              
                                                                                                                                  
                                       4 4  Maintenance                             19     1     0     0     0     0    27     4  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    19     1     0     0     0     0              
                                                                                                                                  
                                                                                                                                  
S0432-AML, Age 70+, R115777            1 1  R115777 600mg BID x 21d q28d     296    83     0     0     0     0     0              
                                         2  R115777 600mg BID x 7d q14d             90     0     0     0     0     0              
                                         3  R115777 300mg BID x 21d q28d            86     0     0     0     0     0              
                                         4  R115777 300mg BID x 7d q14d             89     0     0     0     0     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                   348     0     0     0     0     0              
                                                                                                                                  
                                       2 5  R115777 600mg BID x 21d q28d             7     0     0     0     0     0              
                                         6  R115777 600mg BID x 7d q14d              2     0     0     0     0     0              
                                         7  R115777 300mg BID x 21d q28d             7     0     0     0     0     0              
                                         8  R115777 300mg BID x 7d q14d              2     0     0     0     0     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    18     0     0     0     0     0              
                                                                                                                                  
                                                                                                                                  
S0521-APL,Low/Int Risk, Maint vs Obs   1 1  ATRA + ARA-C + Daunorubicin      550   105    44    15     0     0     0    86    40  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                   105    44    15     0     0     0              
                                                                                                                                  
                                       2 2  Consolidation                           92    43    21     7     0     0    86    40  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    92    43    21     7     0     0              
                                                                                                                                  
                                       3 3  ATRA + 6MP + MTX                 440    33    23    13     8     6     2    86    40  
                                         4  Observation                             27    18     8     3     0     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    60    41    21    11     6     2              
                                                                                                                                  
                                       4 5  Gemtuzumab Ozogamicin                    1     1     0     0     0     0    86    40  
                                                                 
<PRE>                                                                                                                             
03 SEP 2010 05:51                     LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES                                      
                                                                                                                                  
                                                                                       REGS. REGS. REGS. REGS. REGS.              
                                       R                                                LAST  LAST  LAST  LAST  LAST  # of  # of  
                                       E                                   ACCR. TOTAL    12     6     3    30     7  ACT.  CURR  
STUDY                                  G ARM                                GOAL REGS. Month Month Month  DAYS  DAYS INSTs  IRBs  
-------------------------------------- - --------------------------------- ----- ----- ----- ----- ----- ----- ----- ----- -----  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                     1     1     0     0     0     0              
                                                                                                                                  
                                                                                                                                  
S0530-ALL, Rel/Refr, Clofar. + Ara-C   1 1  Cytarabine + Clofarabine          35    37     0     0     0     0     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    37     0     0     0     0     0              
                                                                                                                                  
                                       2 2  Consolidation                            1     0     0     0     0     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                     1     0     0     0     0     0              
                                                                                                                                  
                                                                                                                                  
S0535-APL,High Risk, ATRA/arsenic/GO   1 1  ATRA + G.O. + Arsenic             77    34    25     9     1     0     0   145    52  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    34    25     9     1     0     0              
                                                                                                                                  
                                       2 2  Consolidation                           29    21    13     5     1     1   145    52  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    29    21    13     5     1     1              
                                                                                                                                  
                                       3 3  ATRA + 6-MP + MTX                       12    11     8     3     3     2   145    52  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    12    11     8     3     3     2              
                                                                                                                                  
                                                                                                                                  
S0605-AML, del5q, Age 60+, Revlimid    1 1  Revlimid                          45    41     8     1     1     0     0    58    22  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    41     8     1     1     0     0              
                                                                                                                                  
                                       2 2  Maintenance Revlimid                    12     2     0     0     0     0    58    22  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    12     2     0     0     0     0              
                                                                                                                                  
                                                                                                                                  
S0703-AML, age 60+, Azacitidine G.O.   1 1  Hydroxyurea/Azacitidine/G.O.     153    90    59    23     6     0     0   183    55  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    90    59    23     6     0     0              
                                                                                                                                  
                                       2 2  Azacitidine/G.O.                 139    25    20     9     5     1     0   183    55  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    25    20     9     5     1     0              
                                                                                                                                  
                                       3 3  Azacitidine                      139    20    17     8     5     1     0   183    55  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    20    17     8     5     1     0              
                                                                                                                                  
                                                                                                                                  
S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT  1 1  Induction/Consolidation           94     1     1     1     1     1     0    72    15  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                     1     1     1     1     1     0              
                                                                                                                                  
                                                                                                                                  
S0919-Rel AML: Pravastatin+Ida+Ara-C   1 1  Pravastatin+Idarubicin+Ara-C      55     7     7     5     4     0     0    94    34  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                     7     7     5     4     0     0              
                                                                                                                                  
                                       2 2  Pravastatin+Idarubicin+Ara-C             2     2     2     1     1     0    94    34  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                     2     2     2     1     1     0              
                                                                                                                                  
                                                                                                                                  
C10403-ALL <30 yrs-Ped,Chemo. Regimen  1 1  Sequential Chemotherapy          300    27    21    12     5     1     0   114    48  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    27    21    12     5     1     0              
                                                                                                                                  
                                                                                                                                  
C10404-CLL, Flu/Rituxan combinations   1 1  Flu/Rituximab                    300     2     2     0     0     0     0    94    54  
                                         2  Flu/Rituximab/Lenalidomide               1     0     0     0     0     0              
                                         3  Flu/Cy/Rituximab                         3     3     2     1     1     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                 
<PRE>                                                                                                                             
03 SEP 2010 05:51                     LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES                                      
                                                                                                                                  
                                                                                       REGS. REGS. REGS. REGS. REGS.              
                                       R                                                LAST  LAST  LAST  LAST  LAST  # of  # of  
                                       E                                   ACCR. TOTAL    12     6     3    30     7  ACT.  CURR  
STUDY                                  G ARM                                GOAL REGS. Month Month Month  DAYS  DAYS INSTs  IRBs  
-------------------------------------- - --------------------------------- ----- ----- ----- ----- ----- ----- ----- ----- -----  
                                                                                     6     5     2     1     1     0              
                                                                                                                                  
                                                                                                                                  
C10603-PKC 412, blinded, FLT3 AML      1 Total Registrations                        13    10     8     5     4     1   121    64  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    13    10     8     5     4     1              
                                                                                                                                  
                                                                                                                                  
E1905-MDS/CMMoL/AML-TLD,Aza+/-MS-275   1 1  Azacitidine                      123     8     0     0     0     0     0   112    57  
                                         2  Azacitidine + MS-275                    14     2     1     0     0     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    22     2     1     0     0     0              
                                                                                                                                  
                                                                                                                                  
E2905-MDS, Len vs Len + Epo            1 Total Registrations                        12     9     4     3     0     0   127    80  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    12     9     4     3     0     0              
                                                                                                                                  
                                                                                                                                  




















































                                                                 

45 rows selected.

03 SEP 2010 05:51                             LEUK Open Studies with No Registrations                                             
                                                                                                                                  
Study                                    Registration/Phase                  Open Date                                            
---------------------------------------- ----------------------------------- ---------                                            
S0805 Ph+ ALL, Dasatinib/CVAD +/- BMT    2 Maintenance                       01-Sep-09                                            
                                         3 Allogeneic transplantation        01-Sep-09                                            
                                         4 Single-Agent Dasatinib            01-Sep-09                                            
S0910 Rel ph-,B-ALL,Epratuzumab+Cy+Clo   1 Registration                      15-Aug-10                                            















                                                                 

4 rows selected.


no rows selected

03 SEP 2010 05:51                                                                                                        page         1
LEUK SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES                                                                         
                                                                                                                                       
                                       R                                                                                               
                                       E                                                                       TOTAL                   
STUDY                                  G ARM                               SEGMENT                             REGS.                   
-------------------------------------- - --------------------------------- ----------------------------------- -----                   
S0106-AML, Mylotarg/Ara-C/Daunomycin   1 1  ARA-C + Daunomycin + Mylotarg   01: Initial Induction Mylotarg       317                   
                                         1  ARA-C + Daunomycin + Mylotarg   02: Re-induction                      53                   
                                         2  ARA-C + Daunomycin              01: Initial Induction Mylotarg       319                   
                                         2  ARA-C + Daunomycin              02: Re-induction                      67                   
                                                                                                                                       
                                       2 3  ARA-C Consolidation             01: ARA-C Consolidation              402                   
                                         3  ARA-C Consolidation             02: ARA-C Consolidation              228                   
                                         3  ARA-C Consolidation             03: ARA-C Consolidation              322                   
                                                                                                                                       
                                       3 4  Mylotarg                        01: Post-Consolidation Mylotarg       90                   
                                         4  Mylotarg                        02: Post-Consolidation Mylotarg       28                   
                                         4  Mylotarg                        03: Post-Consolidation Mylotarg       21                   
                                                                                                                                       
                                                                                                                                       
S0333-Non-L3 ALL, Double Induction     4 4  Maintenance                     01: Maintenance Course 1              19                   
                                         4  Maintenance                     02: Maintenance Course 2              15                   
                                         4  Maintenance                     03: Maintenance Course 3              13                   
                                         4  Maintenance                     04: Maintenance Course 4              11                   
                                                                                                                                       
                                                                                                                                       
S0432-AML, Age 70+, R115777            1 1  R115777 600mg BID x 21d q28d    01: Tx days 1-21                      83                   
                                         1  R115777 600mg BID x 21d q28d    02: Tx days 1-21                      37                   
                                         1  R115777 600mg BID x 21d q28d    03: Tx days 1-21                      23                   
                                         1  R115777 600mg BID x 21d q28d    04: Tx days 1-21                      17                   
                                         1  R115777 600mg BID x 21d q28d    05: Tx days 1-21                       6                   
                                         1  R115777 600mg BID x 21d q28d    06: Tx days 1-21                       6                   
                                         1  R115777 600mg BID x 21d q28d    07: Tx days 1-21                       1                   
                                         2  R115777 600mg BID x 7d q14d     01: Tx days 1-7, 15-21                90                   
                                         2  R115777 600mg BID x 7d q14d     02: Tx days 1-7, 15-21                52                   
                                         2  R115777 600mg BID x 7d q14d     03: Tx days 1-7, 15-21                26                   
                                         2  R115777 600mg BID x 7d q14d     04: Tx days 1-7, 15-21                18                   
                                         2  R115777 600mg BID x 7d q14d     05: Tx days 1-7, 15-21                11                   
                                         2  R115777 600mg BID x 7d q14d     06: Tx days 1-7, 15-21                 9                   
                                         2  R115777 600mg BID x 7d q14d     07: Tx days 1-7, 15-21                 5                   
                                         2  R115777 600mg BID x 7d q14d     08: Tx days 1-7, 15-21                 4                   
                                         2  R115777 600mg BID x 7d q14d     09: Tx days 1-7, 15-21                 2                   
                                         2  R115777 600mg BID x 7d q14d     10: Tx days 1-7, 15-21                 2                   
                                                                    
03 SEP 2010 05:51                                                                                                        page         2
LEUK SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES                                                                         
                                                                                                                                       
                                       R                                                                                               
                                       E                                                                       TOTAL                   
STUDY                                  G ARM                               SEGMENT                             REGS.                   
-------------------------------------- - --------------------------------- ----------------------------------- -----                   
S0432-AML, Age 70+, R115777            1 2  R115777 600mg BID x 7d q14d     11: Tx days 1-7, 15-21                 2                   
                                         2  R115777 600mg BID x 7d q14d     12: Tx days 1-7, 15-21                 2                   
                                         2  R115777 600mg BID x 7d q14d     13: Tx days 1-7, 15-21                 2                   
                                         2  R115777 600mg BID x 7d q14d     14: Tx days 1-7, 15-21                 1                   
                                         2  R115777 600mg BID x 7d q14d     15: Tx days 1-7, 15-21                 1                   
                                         2  R115777 600mg BID x 7d q14d     16: Tx days 1-7, 15-21                 1                   
                                         2  R115777 600mg BID x 7d q14d     17: Tx days 1-7, 15-21                 1                   
                                         2  R115777 600mg BID x 7d q14d     18: Tx days 1-7, 15-21                 1                   
                                         3  R115777 300mg BID x 21d q28d    01: Tx days 1-21                      86                   
                                         3  R115777 300mg BID x 21d q28d    02: Tx days 1-21                      46                   
                                         3  R115777 300mg BID x 21d q28d    03: Tx days 1-21                      30                   
                                         3  R115777 300mg BID x 21d q28d    04: Tx days 1-21                      21                   
                                         3  R115777 300mg BID x 21d q28d    05: Tx days 1-21                      16                   
                                         3  R115777 300mg BID x 21d q28d    06: Tx days 1-21                      10                   
                                         3  R115777 300mg BID x 21d q28d    07: Tx days 1-21                       8                   
                                         3  R115777 300mg BID x 21d q28d    08: Tx days 1-21                       6                   
                                         3  R115777 300mg BID x 21d q28d    09: Tx days 1-21                       4                   
                                         3  R115777 300mg BID x 21d q28d    10: Tx days 1-21                       3                   
                                         3  R115777 300mg BID x 21d q28d    11: Tx days 1-21                       1                   
                                         3  R115777 300mg BID x 21d q28d    12: Tx days 1-21                       1                   
                                         3  R115777 300mg BID x 21d q28d    13: Tx days 1-21                       1                   
                                         3  R115777 300mg BID x 21d q28d    14: Tx days 1-21                       1                   
                                         3  R115777 300mg BID x 21d q28d    15: Tx days 1-21                       1                   
                                         3  R115777 300mg BID x 21d q28d    99: Tx days 1-21                       1                   
                                         4  R115777 300mg BID x 7d q14d     01: Tx days 1-7, 15-21                89                   
                                         4  R115777 300mg BID x 7d q14d     02: Tx days 1-7, 15-21                48                   
                                         4  R115777 300mg BID x 7d q14d     03: Tx days 1-7, 15-21                23                   
                                         4  R115777 300mg BID x 7d q14d     04: Tx days 1-7, 15-21                20                   
                                         4  R115777 300mg BID x 7d q14d     05: Tx days 1-7, 15-21                12                   
                                         4  R115777 300mg BID x 7d q14d     06: Tx days 1-7, 15-21                 9                   
                                         4  R115777 300mg BID x 7d q14d     07: Tx days 1-7, 15-21                 8                   
                                         4  R115777 300mg BID x 7d q14d     08: Tx days 1-7, 15-21                 7                   
                                         4  R115777 300mg BID x 7d q14d     09: Tx days 1-7, 15-21                 4                   
                                         4  R115777 300mg BID x 7d q14d     10: Tx days 1-7, 15-21                 2                   
                                         4  R115777 300mg BID x 7d q14d     11: Tx days 1-7, 15-21                 1                   
                                         4  R115777 300mg BID x 7d q14d     12: Tx days 1-7, 15-21                 1                   
                                         4  R115777 300mg BID x 7d q14d     13: Tx days 1-7, 15-21                 1                   
                                                                    
03 SEP 2010 05:51                                                                                                        page         3
LEUK SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES                                                                         
                                                                                                                                       
                                       R                                                                                               
                                       E                                                                       TOTAL                   
STUDY                                  G ARM                               SEGMENT                             REGS.                   
-------------------------------------- - --------------------------------- ----------------------------------- -----                   
S0432-AML, Age 70+, R115777            1 4  R115777 300mg BID x 7d q14d     14: Tx days 1-7, 15-21                 1                   
                                         4  R115777 300mg BID x 7d q14d     15: Tx days 1-7, 15-21                 1                   
                                         4  R115777 300mg BID x 7d q14d     16: Tx days 1-7, 15-21                 1                   
                                                                                                                                       
                                       2 5  R115777 600mg BID x 21d q28d    01: Tx days 1-21                       7                   
                                         5  R115777 600mg BID x 21d q28d    02: Tx days 1-21                       6                   
                                         5  R115777 600mg BID x 21d q28d    03: Tx days 1-21                       3                   
                                         5  R115777 600mg BID x 21d q28d    04: Tx days 1-21                       2                   
                                         6  R115777 600mg BID x 7d q14d     01: Tx days 1-7, 15-21                 2                   
                                         6  R115777 600mg BID x 7d q14d     02: Tx days 1-7, 15-21                 1                   
                                         6  R115777 600mg BID x 7d q14d     05: Tx days 1-7, 15-21                 1                   
                                         7  R115777 300mg BID x 21d q28d    01: Tx days 1-21                       7                   
                                         7  R115777 300mg BID x 21d q28d    02: Tx days 1-21                       4                   
                                         7  R115777 300mg BID x 21d q28d    03: Tx days 1-21                       2                   
                                         7  R115777 300mg BID x 21d q28d    04: Tx days 1-21                       2                   
                                         7  R115777 300mg BID x 21d q28d    05: Tx days 1-21                       2                   
                                         7  R115777 300mg BID x 21d q28d    06: Tx days 1-21                       1                   
                                         7  R115777 300mg BID x 21d q28d    07: Tx days 1-21                       1                   
                                         7  R115777 300mg BID x 21d q28d    08: Tx days 1-21                       1                   
                                         7  R115777 300mg BID x 21d q28d    09: Tx days 1-21                       1                   
                                         8  R115777 300mg BID x 7d q14d     01: Tx days 1-7, 15-21                 2                   
                                                                                                                                       
                                                                                                                                       
S0521-APL,Low/Int Risk, Maint vs Obs   2 2  Consolidation                   01: Consolidation cycle 1: arsenic    92                   
                                         2  Consolidation                   02: Consolidation cycle 2: arsenic    73                   
                                         2  Consolidation                   03: Consolidation cycle 3:ATRA/DNR    64                   
                                         2  Consolidation                   04: Consolidation cycle 4:ATRA/DNR    56                   
                                                                                                                                       
                                                                                                                                       
S0530-ALL, Rel/Refr, Clofar. + Ara-C   1 1  Cytarabine + Clofarabine        01: Induction cycle 1                 37                   
                                         1  Cytarabine + Clofarabine        02: Induction cycle 2                  2                   
                                                                                                                                       
                                                                                                                                       
S0535-APL,High Risk, ATRA/arsenic/GO   2 2  Consolidation                   02: Consol. 1: arsenic                29                   
                                         2  Consolidation                   03: Consol. 2: arsenic                16                   
                                         2  Consolidation                   04: Consol. 3: ATRA/daunomycin        12                   
                                         2  Consolidation                   05: Consol. 4: ATRA/daunomycin        10                   
                                                                    
03 SEP 2010 05:51                                                                                                        page         4
LEUK SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES                                                                         
                                                                                                                                       
                                       R                                                                                               
                                       E                                                                       TOTAL                   
STUDY                                  G ARM                               SEGMENT                             REGS.                   
-------------------------------------- - --------------------------------- ----------------------------------- -----                   
S0535-APL,High Risk, ATRA/arsenic/GO   2 2  Consolidation                   06: Consol. 5: G.O.                    9                   
                                         2  Consolidation                   07: Consol. 6: G.O.                    9                   
                                                                                                                                       
                                                                                                                                       
S0605-AML, del5q, Age 60+, Revlimid    2 2  Maintenance Revlimid            02: Cycle 2: Maint. 1                 12                   
                                         2  Maintenance Revlimid            03: Cycle 3: Maint. 2                  3                   
                                         2  Maintenance Revlimid            04: Next cycle: Next Maint.            3                   
                                         2  Maintenance Revlimid            05: Next cycle: Next Maint.            3                   
                                         2  Maintenance Revlimid            06: Next cycle: Next Maint.            1                   
                                         2  Maintenance Revlimid            07: Next cycle: Next Maint.            1                   
                                                                                                                                       
                                                                                                                                       
S0703-AML, age 60+, Azacitidine G.O.   1 1  Hydroxyurea/Azacitidine/G.O.    01: Cycle 1: Induction                90                   
                                         1  Hydroxyurea/Azacitidine/G.O.    02: Cycle 2: Induction                55                   
                                                                                                                                       
                                       3 3  Azacitidine                     04: Maintenance 1: cycle 4            20                   
                                         3  Azacitidine                     05: Maintenance 2: cycle 5            13                   
                                         3  Azacitidine                     06: Maintenance 3: cycle 6            13                   
                                         3  Azacitidine                     07: Maintenance 4: cycle 7            12                   
                                                                                                                                       
                                                                                                                                       
S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT  1 1  Induction/Consolidation         01: Ind/Cons 1: CVAD/Dasatinib         1                   
                                                                                                                                       
                                                                                                                                       
S0919-Rel AML: Pravastatin+Ida+Ara-C   2 2  Pravastatin+Idarubicin+Ara-C    02: Consolidation 1                    2                   
                                                                                                                                       
                                                                                                                                       










                                                                    

114 rows selected.

</PRE><A HREF="http://www.swogstat.org" NAME="SWOG StatCtr Home Page">SWOG StatCtr Home Page</A>                                       

1 row selected.